S-ry We measured levels of basic fibroblast growth factor 
Angiogenic peptides such as basic fibroblast growth factor (FGF-2) appear to have substantial roles in the regulation of tumour growth (Soutter et al., 1993; Nguyen et al., 1994) and therefore may be considered targets for anti-angiogenesis cancer treatments, possibly in conjunction with chemo-or radiotherapy (Jenks, 1994) . Such combined therapies, however, may present subtle problems. For example, we have shown that treatment of xenogafted human tumours with exogenous FGF-2 increases growth rates and decreases hypoxia levels (Leith et al., 1992; Leith and Mitchelson, 1993) . Conversely, administration of suramin, a growth factor receptor-blocking agent, slows tumour growth while increasing steady-state levels of hypoxia (Leith et al., 1992) . Because hypoxic cells are radiation isaant, strategies that rely upon blocking neovascularisation could produce an unfavourable radiotherapeutic situation. With this caveat in mind, we investigated some aspects of tumour biology related to the feasbility of a radiotherapeutic/anti-angiogenesis approach.
We have previously determined steady-state levels of intratumour hypoxia in a large number of xenografted solid human colon cancers in nude mice, and demonstrated that at similar volumes percentages of hypoxia varied from ess than 1% to over 80% (Leith et al., 1991a) . These widely divergent results led to the hypothesis that variabilaity in hypoxia expression might be inversely related to intraneoplastic levels of angiogenic factors such as FGF-2. According to this logic, cells that produce high levels of FGF-2 would generate wellvascularised solid tumours. Then, as a consequence of this putative well-vascularized situation, such neoplasms should in turn express low steady-state levels of hypoxia. Therefore, we determined levels of FGF-2 both in vitro and in vivo for the human colon tumour cell line, clone A, chosen because hypoxia levels in these neoplasms are low (-,3%) (Leith et al., 1991a) . Based on our hypothesis, we a priori predicted that high cellular levels of FGF-2 would be present. Unexpectedly, however, we found that FGF-2 levels in vitro on a per cell basis were not only very low, but were also several orders of magnitude less than in vivo levels.
Materils ad
Ceu line The clone A cell lne was established in 1978, at the Roger WViliams Cancer Center, Providence, RI, USA, from a biopsy specmen from a male patient with a poorly to moderately differentiated primary colonic adenocarcinoma. The primary tumour was found to be heterogeneous, and two cell lines (clones A and D) which differ significantly in morphology and chromosomal number were established. Details on subpopulation isolation have been published (Calabresi et at., 1979; Dexter et al., 1981) . For (Leith et al., 1991b) . Cell yields from enzymatcally disaggregted clone A neoplasms (n = 9) were 5.58 ± 1.86 x 10' cells mg-' (s.e.m.) and median cell volumes were 17001m3.
A number of points may be made from the results shown in Tables I and H . First, on a per cell basis, both fed and unfed plateau phase cells show decreased levels of FGF-2 (1.4 and 2.1 pg 10-' cells respectively) as compared with exponentially growing cells (7.7 pg 10-6 cells), indicating that growth status and/or cell cycle position affects FGF-2 levels.
Second, exposure of exponentially growing cells (about 5 x 10' cells cm -) to a hypoxic environment for 16 h yielded (Leith et al., 1991a) . The resolution to this paradox is, however, indicated (Table I) .
Second, levels of FGF-2 in unfed plateau phase cultures were low as compared with exponentially growing cultures. T1his might indicate a cell cycle block induced by the hypoxia in GI (Rice et al., 1985) . While, to our knowledge, there have been no studies on levels of FGF-2 per cell as an explicit function of cell cycle phase, Bost and Hjelmeland (1993) showed that levels of a major 7.0 kb FGF-2 transcript in retinal epithelium decreased by a factor of about 15 in exponential vs confluent cultures. Additionally, not only does the transcript level decrease, the half-life of the transcript decreases from about 24 h to about 17 h. Such changes are probably allied to the decreased FGF-2 protein levels we find in fed and unfed plateau phase clone A cells. With regard to these two points, cell cycle distributions (G1, S, G2+M) in exponentially growing and unfed plateau phase cultures of clone A cells are respectively about 53, 24 and 22%, and 78, 14 and 8% (Bliven et al., 1987) . The simplest initial assumption would be that the concentration of FGF-2 per cell (i.e. fg pm-3) does not change throughout the cell cycle, and that measured levels change only as the change in relative cell volume as cells progress from G1 to G2 + M (Bliven et al., 1987) . However, normalisation of cellular FGF-2 contents using such a volumetric approach based on the distribution of cells through the cell cycle does not account for the approximately 70% decrease in average cellular FGF-2 levels (Table I) . Indeed, FGF-2 levels would only decrease by about 15% using this approach. Therefore, it appears that decreased growth rates in the plateau phase are associated with an absolute decrease in cellular FGF-2 levels. In this regard, it is important to note that our determinations of FGF-2 levels in fed and unfed plateau phase cultures were done under conditions (e.g. use of 175 cm2 flasks containing respecively about 2.5 x 106 and 5 x I0 cells cm2 with a medium depth of 0.286 cm) that might be associated with respiration-induced hypoxia (Koch, 1979) . Although respiratory rates of plateau phase cells are often less than that in exponential growth, we do not know respiratory rates (mol s-' per cell) of either exponential or plateau phase clone A cells. This caveat could also apply to the work of Bost and Hjelneland (1993) cited above.
Third, assay of FGF-2 levels in clone A cultures in vivo shortly after establishment from disaggregated neoplasms were not different from levels seen in established cultures (Table I) . Moreover, FGF-2 levels in clone A cells (e.g. -2 pg 10-6 cells in in vitro unfed plateau cultures) are among the lowest in 14 different human colon cancer cell lines studied in vitro to date (J Leith, unpublished data).
Fourth, because the ribonuclease protection assay degrades probe-target duplexes containing even a single base pair mismatch, the assay was specific for human FGF-2 transcripts and showed no differences in FGF-2 mRNA levels as normalised to human P-actin mRNA levels between preparations from clone A cells in vitro and whole tumours. This strongly implies that the increased levels of FGF-2 seen in protein assays are derived from the host. We therefore do not view the increased levels of FGF-2 seen in vivo as resulting from biochemical/molecular changes in clone A cells per se.
Another possibility as to why FGF-2 levels are unpredictably high in vivo is storage of FGF-2 by heparan sulphate proteoglycans (HSPGs) in either cell-attached or extracellular compartments (Vlodavsky et al., 1991) . Our measurements of FGF-2 levels per mg of tumour do not provide insight into the microscopic distribution of FGF-2, and we do not know levels of FGF-2-binding HSPGs in clone A neoplasms. However, significant levels of HSPGs have been shown in other tumour systems (Esko et al., 1988) , and there is a priori no reason to assume otherwise for clone A tumours. FGF-2 released from cells could be bound to HSPGs for a sufficient amount of time to account for the increased levels seen in vivo. Indeed, FGF-2 binding to ECM HSPGs has been described as 'highly stable' (Vlodavsky et al., 1991) , although it will be a function of factors such as specific tumour heparanase levels, which vary significantly (Nakajima et al., 1990; Vlodavsky et al., 1991 , we estimate that average size and 95% confidence limits of the parenchymal compartment (P) is 9.5% (± 7.8%) of the total tumour, with the remaining 90.5% therefore being non-tumour tissues (NP compartment). We calculate the fractional volume (FV) of the P compartment as follows: is statistically significant (t= 3.89, P <0.05; Goldstein, 1964) , and indicates that FGF-2 levels in P and (P + NP) compartments are strongly correlated, as would be expected. We also note that if the increase in FGF-2 levels in whole tumours was a reflection of increases in levels in parenchymal tumour cells only (that is if levels in NP were constant), the slope of this curve im such a situation would be predicted to be about 0.22. The 95% confidence limits on the slope of the response are ± 0.413. This value is less than that for the lower limit on the slope given by the 95% confidence limits cited above (i.e. 0.27), which suggests an additional FGF-2 source. Related to this, absolute levels of FGF-2 vary widely from tumour to tumour. Why there should be such inter-tumour variation in steady-state levels of FGF-2 for neoplasms of the same average size requires discussion. Neither the levels of FGF-2 in parenchymal tumour cells nor the levels in whole tumour extracts showed a significant correlation with tumour volume over the limited range of volumes studied herein (respective correlation coefficients were -0.22 and -0.12). However, as noted above, there is a large variation in the fractional volume of the tumour occupied by parenchymal cells (95% confidence limits approximately 1.8-17.3%). Additionally, because at this average tumour size, of the order of 27% ±7% (95% confidence limits) of the P compartment may be macrophages , this indicates that the relative percentage of macrophages in any given neoplasm could vary in the extreme from possibly as low as 0.4% to as high as 6% of total cells in the P compartment, i.e. a difference of about 15-fold. On this point, the range of FGF-2 values expressed among different tumours as either pg 10-6 cells or pgmg-1 tumour was roughly of the same order of magnitude. These data imply that the high levels of FGF-2 seen in vivo as well as the variability from tumour to tumour could be the result of host cells. We note also that. although there was no dependence of FGF-2 levels on tumour volume, there was a strong inverse correlation of (log) FGF-2 levels (pg 10-6 cells) Related to this issue of the inverse correlation between tumour cellularity and FGF-2 levels per cell seen in vivo is the fact that macrophages contain FGF-2 (Frautschy et al., 1991; Motoo et al., 1991; Logan et al., 1992; Greisler et al., 1993; Hughes et al., 1993) . Indeed, Baird et al. (1985) indicated that FGF-2 levels in activated peritoneal macrophages were approximately S ng 10-6 cells, a level high enough to be consistent with a macrophage-endothelial cell mitogenic paracrine loop. In this regard, a review of the literature indicates that typical macrophage percentages in cell suspensions from disaggregated sarcomas and carcinomas (geometric means and 95% confidence limits) are respectively about 30% (19-48%) and 34% (20-57%) (Evans, 1977; Siemann et al., 1981; Milas et al., 1987; West et al., 1987) . Therefore, the high levels of FGF-2 found in clone A tumours may be coming from the intermixed host cells. Indeed, calculation of a rough weighted average of FGF-2 concentrations as measured in the disaggregate assuming 90% parenchymal tumour cells and 10% macrophages using the FGF-2 values for unfed plateau phase clone A cells (Table I ) and the macrophage results from Baird et al. (1985) indicates that the presence of a significant fraction of macrophages in the disaggregate could easily lead to the values listed in Table I Average FGF-2 levels in clone A neoplasms are approximately 24 pg of FGF-2 per mg of tumour (24 ng ml -, assuming unit density) (Table I ). This calculation neglects any correction for the necrotic component of clone A neoplasms, which is approximately 10% at a volume of 750 mm3 Leith and Michelson, 1994 (JT Leith, unpublished data, 1994 JT Leith, unpublished data, 1994 ). It may be necessary to investigate whether significant levels of other growth factors are also present in necrotic regions. To our knowledge, little attention has been given to the partitioning of growth factors between viable and necrotic portions of neoplasms. In justification, we note that the necrotic portion of solid tumours has been postulated as a site for production of growth-inhibitory proteins (Freyer, 1988 (D'Amore & Smith, 1993; Schwartz, 1993) . This finding is consistent with the low steady-state levels of intratumour hypoxia observed in clone A neoplasms (Leith et al., 1991a) .
In summary, although these results still support the hypothesis that levels of angiogenic growth factors such as FGF-2 in vivo may be related to hypoxia, the complex biological processes involved in these results require further study. As noted above, because these factors may be derived from host cells rather than parenchymal tumour cells, the variability in steady-state levels of intra-tumour hypoxia among various tumour models could result from host cellrelated paracrine effects. This speculation is supported by the fact that levels of FGF-2 in clone A cells appear insufficient to create an effective paracrine loop. However, long-term binding of FGF-2 to HSPGs could provide a functional link between apparently low instantaneous cellular levels and high steady-state tumour levels. Separation of host from tumour cells by centrifugal elutriation (West et al., 1987) with ELISA analysis of subpopulation growth factor levels to address these possibilities is therefore an important future goal. Additionally, there are numerous dynamic interconnections among growth factors/cytokines etc. Leith, 1993, 1994) whose functional significance in vivo is poorly determined at present. Because potent synergistic interactions have been shown to occur between growth factors such as FGF-2 and VEGF (Pepper et al., 1992; Goto et al., 1993) , the levels of other stimulatory angiogenic factors (e.g. VEGF) need to be defined to determine which growth factor(s) is(are) of importance in determination of steady-state levels of intraneoplastic hypoxia. Lastly, these results indicate that in vitro studies alone may be inadvertently misleading with regard to the accuracy of models of solid tumour physiology, illustrating the necessity of appropriate in vivo measurements (Soutter et al., 1993) .
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